Free Trial

Silence Therapeutics (SLN) Competitors

Silence Therapeutics logo
$6.34 +0.06 (+0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$6.32 -0.02 (-0.39%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLN vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Silence Therapeutics vs. Its Competitors

Silence Therapeutics (NASDAQ:SLN) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Silence Therapeutics presently has a consensus price target of $33.83, suggesting a potential upside of 433.65%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Silence Therapeutics and Silence Therapeutics both had 1 articles in the media. Silence Therapeutics' average media sentiment score of 1.89 equaled 180 Life Sciences'average media sentiment score.

Company Overall Sentiment
Silence Therapeutics Very Positive
180 Life Sciences Very Positive

180 Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -260.55%. 180 Life Sciences' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence Therapeutics-260.55% -56.17% -33.96%
180 Life Sciences N/A N/A N/A

98.7% of Silence Therapeutics shares are held by institutional investors. 4.1% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

180 Life Sciences has lower revenue, but higher earnings than Silence Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$43.26MN/A-$45.31M-$1.50-4.23
180 Life SciencesN/AN/AN/AN/AN/A

Summary

Silence Therapeutics beats 180 Life Sciences on 6 of the 9 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLN vs. The Competition

MetricSilence TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-4.239.0528.0720.05
Price / SalesN/A757.64448.5799.42
Price / CashN/A165.2136.2258.56
Price / Book1.425.168.665.87
Net Income-$45.31M$30.99M$3.25B$258.55M
7 Day Performance4.97%7.74%4.20%2.23%
1 Month Performance9.31%16.18%10.82%12.76%
1 Year Performance-69.84%-1.03%34.70%19.36%

Silence Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLN
Silence Therapeutics
2.0273 of 5 stars
$6.34
+1.0%
$33.83
+433.6%
-70.2%$0.00$43.26M-4.23100Positive News
ATNFW
180 Life Sciences
N/A$0.01
+14.1%
N/A+11.8%$0.00N/A0.007Positive News
Gap Down
High Trading Volume
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.16
-9.3%
N/AN/A$0.00$106.21K0.0040Positive News
Gap Up
ALVOW
Alvotech
N/A$1.96
+18.8%
N/A-27.2%$0.00$585.60M0.004Positive News
Gap Up
High Trading Volume
ARAV
Aravive
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.02
flat
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.10
-2.8%
N/AN/A$0.00$38.00M0.0070Gap Down
BTMDW
biote
N/A$0.01
+0.7%
N/A-97.2%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.05
+30.4%
N/A-65.8%$0.00N/A0.008Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:SLN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners